Business Description
Agenus Inc
NAICS : 325414
SIC : 2836
ISIN : US00847G7051
Description
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.57 | |||||
| Equity-to-Asset | -1.23 | |||||
| Debt-to-Equity | -0.27 | |||||
| Debt-to-EBITDA | -1.01 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -14.19 | |||||
| Beneish M-Score | -0.83 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -5.1 | |||||
| 3-Year EBITDA Growth Rate | 15 | |||||
| 3-Year EPS without NRI Growth Rate | 12.4 | |||||
| 3-Year FCF Growth Rate | 7.5 | |||||
| 3-Year Book Growth Rate | 26.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 14.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 35.01 | |||||
| 9-Day RSI | 37.05 | |||||
| 14-Day RSI | 38.33 | |||||
| 6-1 Month Momentum % | -78.07 | |||||
| 12-1 Month Momentum % | -78.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.19 | |||||
| Quick Ratio | 0.19 | |||||
| Cash Ratio | 0.17 | |||||
| Days Sales Outstanding | 12.86 | |||||
| Days Payable | 96.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.2 | |||||
| Shareholder Yield % | -49.54 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -17.88 | |||||
| Operating Margin % | -62.83 | |||||
| Net Margin % | -141.9 | |||||
| FCF Margin % | -106.46 | |||||
| ROA % | -79.22 | |||||
| ROIC % | -27.72 | |||||
| ROC (Joel Greenblatt) % | -57.93 | |||||
| ROCE % | -250.78 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.08 | |||||
| EV-to-EBIT | -1.3 | |||||
| EV-to-Forward-EBIT | -5.07 | |||||
| EV-to-EBITDA | -1.56 | |||||
| EV-to-Revenue | 0.75 | |||||
| EV-to-Forward-Revenue | 0.97 | |||||
| EV-to-FCF | -0.71 | |||||
| Price-to-Median-PS-Value | 0.01 | |||||
| Earnings Yield (Greenblatt) % | -76.92 | |||||
| FCF Yield % | -265.93 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AGEN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Agenus Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 160.427 | ||
| EPS (TTM) ($) | -68.77 | ||
| Beta | 1.37 | ||
| Volatility % | 80.55 | ||
| 14-Day RSI | 38.33 | ||
| 14-Day ATR ($) | 0.285211 | ||
| 20-Day SMA ($) | 3.17425 | ||
| 12-1 Month Momentum % | -78.64 | ||
| 52-Week Range ($) | 2.5 - 19.688 | ||
| Shares Outstanding (Mil) | 23.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Agenus Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Agenus Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Agenus Inc Frequently Asked Questions
What is Agenus Inc(AGEN)'s stock price today?
The current price of AGEN is $2.75. The 52 week high of AGEN is $19.69 and 52 week low is $2.50.
When is next earnings date of Agenus Inc(AGEN)?
The next earnings date of Agenus Inc(AGEN) is 2025-03-14 Est..
Does Agenus Inc(AGEN) pay dividends? If so, how much?
Agenus Inc(AGEN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers